Thirty-nine articles were included, with 21 meta-analyses and 18 qualitative systematic reviews. 5 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Research
27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
The evidence of a preventive treatment effect aimed at vascular risk factors on cognitive decline and dementia in later life is scarce and mostly based on secondary outcome parameters. 4 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Resource accounts of behavioral aging postulate that age-associated impairments within and across intellectual and sensory domains reflect, in part, a common set of senescent alterations in the neurochemistry and neuroanatomy of the aging brain. 5 key findings →
Design: longitudinal study Participants: 516 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Higher cardiovascular risk burden may predict decline in episodic memory, working memory, and perceptual speed and is associated with neurodegeneration and vascular lesions in the brain. 4 key findings →
Participants: 378 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Late-life lower BMI relates to faster rates of decline in cognition, specifically semantic memory and episodic memory, in both blacks and whites. 2 key findings →
Design: cohort study Participants: 2,134 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Our findings in CPAP+ participants suggest that CPAP treatment of SDB may delay progression of cognitive impairment. 4 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
There are variations in the interventions, such as location and dosage. 5 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
57/100
Further exploration of relationships between oral health and cognition is warranted. 3 key findings →
Participants: 2,355 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
57/100
Single centre population based cross sectional door to door study. 4 key findings →
Participants: 4,971 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Although previous research has shown that initiation of postmenopausal estrogen hormone therapy (HT) in late life increases risk of dementia, animal studies and some observational studies have suggested that midlife use of HT may be beneficial; however, this has not been rigorously investigated in large population-based studies. 4 key findings →
Participants: 1,524 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In cognitively unimpaired (CU) adults at baseline, the risk for progression to dementia increased for every decile increase in the ADI state ranking (hazard ratio = 1.06, 95% confidence interval (1.01-1.11), P = .01). 5 key findings →
Participants: 4,699 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
On average, participants were aged 63 years and had 16 years of education. 5 key findings →
Design: randomized controlled trial Participants: 100 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
All ML models outperformed the MMSE alone. 5 key findings →
Design: longitudinal study Participants: 1,331 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In total, 41 participants consented (n=10, 24% participants with Alzheimer disease; n=11, 27% participants with Lewy body disease; and n=20, 49% controls). 5 key findings →
Design: longitudinal study Participants: 41 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
A total of 110 participants (mean [SD] age, 67.9 [4.6] years; 68 female [61.8%]) were randomized to the experimental group (n = 55) and the sham group (n = 55) and included in the intention-to-treat analysis. 5 key findings →
Participants: 55 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Among the participants, 377 (93.5%) reported subjective memory complaints. 5 key findings →
Design: longitudinal study Participants: 403 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
This study examined the combined effects of StrongerMemory program (brain exercises involving reading, writing, and math) and weekly social engagement on cognitive, behavioral, and emotional outcomes in older adults with subjective cognitive decline (SCD). 4 key findings →
Design: randomized controlled trial Participants: 50 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The application was developed with distinct user and administrator interfaces to support engagement and monitoring. 5 key findings →
Design: systematic review Participants: 100 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Hearing loss is independently associated with accelerated cognitive decline and incident cognitive impairment in community-dwelling older adults. 5 key findings →
Participants: 1,984 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Periodontitis is an oral inflammatory disease and may contribute to low-grade systemic inflammation. 1 key finding →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Moreover, physical activity in the elderly is associated with a decreased risk of mortality, of common chronic illnesses (i.e. cardiovascular disease or osteoarthritis) and of institutionalization as well as with a delay in functional decline. 5 key findings →
Participants: 240 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The results indicate that incorporating MI can positively influence cognitive status, emotional status, and the quality of life in older adults diagnosed with early-stage dementia. 4 key findings →
Design: randomized controlled trial Participants: 55 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Olfactory impairment at baseline was strongly associated with 5-year incidence of cognitive impairment as measured using the MMSE. 4 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Prevalent hemodialysis patients demonstrate significant cognitive decline, particularly within tests of executive function. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
56/100
This analysis combining data from two health systems shows that area deprivation is an independent risk factor for cognitive dysfunction in older adults. 3 key findings →
Design: cross-sectional Participants: 5,186 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →